louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06814535: A Comparative Study on the Impact of Trigger Points Injection of Platelet Rich Plasma Versus Botulinum Toxin on the Relief of Jaw Muscles Myofascial Pain
Official title: A Comparative Study on the Impact of Trigger Points Injection of Platelet Rich Plasma Versus Botulinum Toxin a on the Relief of Jaw Muscles Myofascial Pain
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
PHASE3
Conditions: Patients with Jaw Muscles Myofascial Pain
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-02-07
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims at comparing the effect of trigger points injection of platelet rich plasma and botulinum toxin a on the relief of jaw muscles Myofascial pain .

The 1st group includes 20 patients who are supposed to receive 5 units of botulinum toxin A per trigger point in masseter and/or temporalis muscles.

The 2nd group will receive ,5 ml of PRP per trigger point in masseter and/or temporalis muscles.

The 3rd group will receive .5 ml of physiologic saline per each trigger point in masseter and/or temporalis muscles.

The 1st follow up session will be after 1 week then 1 month then 3 months . The patients are advised to limit excessive Mouth opening, yawning or singing. And when pain episode , theta re advised to take only paracetamol as analgesic drug .

At the follow up sessions ، measuring the interincisal opening , pressure pain threshold using algometer , VAS to measure the intensity of pain , Likert scale , current pain intensity, worst pain intensity and the need to take analgesics in Numbers.

Then comparing the results of these groups to end in rejecting the null hypothesis which says there's an equivalence between the 3 types of injected solutions or accepting it .


Eligibility criteria: Inclusion Criteria:

* patient with myofascial trigger points in masseter or temporalis previously ----\*identified by manual palpation.

  * 18 years or More "Willingness to follow instructions.

Exclusion Criteria:

* therapeutic intervention for myofascial pain in the last view months such as taking medications for pain control or wearing an occlusal splint.

  * Clinical conditions as pregnancy
  * Medical problems that will interfere with the procedure as bleeding disorders.
  * Cognitive impairment or present inadequate cooperation.

Primary outcomes:
measure: Pressure pain threshold
timeFrame: 3 months
measure: Current pain intensity
timeFrame: 3 months
measure: Worst pain intensity
timeFrame: 3 months
Secondary outcomes:
measure: Inter incisal opening
timeFrame: 3 months
measure: Patient satisfaction
timeFrame: 3 months
measure: The need for analgesics
timeFrame: 3 months
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Faculty of dentistry Cairo University
Study officials:
References:
Clinical trial NCT01692535: Evaluation of Video Laryngoscopes in Difficult Airway
Official title: Multicenter Study Evaluating Video Laryngoscopes: The Swiss Video-Intubation Trial (SWIVIT I)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intubation; Difficult
Lead sponsor: Insel Gruppe AG, University Hospital Bern
Sponsor class: OTHER
Collaborators: name: Centre Hospitalier Universitaire Vaudois
name: University Hospital, Geneva
First posted: 2012-09-25
Enrollment: 720
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: In this multicenter study the investigators are going to evaluate the use of six different videolaryngoscopes in patients undergoing elective surgery requiring general anesthesia with intubation. The investigators are hypothesizing that these six videolaryngoscopes will succeed for intubation at first attempt in at least 90% of all cases using a difficult airway simulation with extrication collars. As gold standard, a standard Macintosh blade is being used.

The study consists of 6 arms. Each arm includes 120 patients, sums up to a total of 720 patients.


Eligibility criteria: Inclusion Criteria:

* elective surgery with general anesthesia requiring intubation
* \>18years old
* ASA I-III

Exclusion Criteria:

* known or presumed difficult airway
* risk of pulmonary aspiration
* refusing to participate

Primary outcomes:
measure: First attempt intubation success rate
timeFrame: within 180 seconds
Secondary outcomes:
measure: side effects
timeFrame: 1h and 1 day after surgery
Other outcomes:
Locations:
city: Geneva
country: Switzerland
facility: Hopitaux Universitaires de Geneve HUG
state: GE
city: Lausanne
country: Switzerland
facility: Centre Hospitalier Universitaire Vaudois CHUV
state: VD
city: Bern
country: Switzerland
facility: Bern University Hospital and University of Bern
Study officials:
affiliation: University Dept Anesthesiology and Pain Therapy, University of Berne, Switzerland
name: Robert Greif, MD MME FERC
role: STUDY_CHAIR
References:
citation: Kleine-Brueggeney M, Greif R, Schoettker P, Savoldelli GL, Nabecker S, Theiler LG. Evaluation of six videolaryngoscopes in 720 patients with a simulated difficult airway: a multicentre randomized controlled trial. Br J Anaesth. 2016 May;116(5):670-9. doi: 10.1093/bja/aew058.
citation: Theiler L, Hermann K, Schoettker P, Savoldelli G, Urwyler N, Kleine-Brueggeney M, Arheart KL, Greif R. SWIVIT--Swiss video-intubation trial evaluating video-laryngoscopes in a simulated difficult airway scenario: study protocol for a multicenter prospective randomized controlled trial in Switzerland. Trials. 2013 Apr 4;14:94. doi: 10.1186/1745-6215-14-94.
Clinical trial NCT00298935: Study of the Effectiveness of Osteopathic Manipulative Treatment in Pregnant Women
Official title: Pilot Clinical Trial of Osteopathic Manipulative Treatment (OMT) in Pregnancy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Low Back Pain
Musculoskeletal Diseases
Pregnancy Complications
Keywords: Randomized Controlled Trial
Pregnant Women
Lead sponsor: University of North Texas Health Science Center
Sponsor class: OTHER
Collaborators: name: Osteopathic Heritage Foundations
First posted: 2006-03-03
Enrollment: 146
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether osteopathic manipulative treatment (OMT):

* decreases pain and improves physical functioning in women during the third trimester of pregnancy
* decreases complications during obstetrical delivery
* improves quality of life in the post-partum period

Detailed description: Women experience multiple changes in their anatomy and physiology during pregnancy that may cause pain and adversely affect quality of life. Additionally, about ten percent of women will experience signs and symptoms of pre-eclampsia or pre-term labor during their first pregnancy.

Preliminary studies of osteopathic manipulative treatment (OMT) have demonstrated a decrease in pain during pregnancy, although the mechanisms responsible for this effect are unclear.

Another theory is that osteopathic manipulative treatment (OMT) may help normalize sympathetic outflow, thereby minimizing pregnancy complications. A recently published retrospective study also suggests that pregnant women receiving osteopathic manipulative treatment (OMT) may be at lower risk for pre-term delivery and the presence of meconium during delivery.

Eligibility criteria: Inclusion Criteria:

* Third trimester pregnancy

Exclusion Criteria:

* High risk pregnancy
* Previous use of chiropractic manipulation, osteopathic manipulative treatment (OMT), physical therapy, or therapeutic ultrasound during the current pregnancy

Primary outcomes:
measure: Visual analogue scale for pain, Roland-Morris Disability Questionnaire, and SF-12 Health Status Survey during third trimester of pregnancy and continuing six weeks post-partum
Secondary outcomes:
measure: Occurrence of premature labor and delivery as well as obstetrical complications during delivery
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: Osteopathic Research Center
state: Texas
Study officials:
affiliation: Osteopathic Research Center
name: John C. Licciardone, D.O., M.S.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04299035: ESP Block vs. Traditional Pain Management for ERAS
Official title: Erector Spinae Plane Block Versus Traditional Pain Management for Enhanced Recovery After Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Postoperative Pain
Keywords: Postoperative pain
Erector spinae plane block
Lead sponsor: Soroka University Medical Center
Sponsor class: OTHER
First posted: 2020-03-06
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients undergoing thoracotomy, thoracoscopy or other surgical procedures involving the integrity of the chest wall are always in a special point of interest of both surgical and anesthesiological specialities. Most of the patients will describe the pain after thoracic surgery as severe. It might lead to a number of serious complications: respiratory failure due to splinting; inability to clear secretions by effective coughing, with resulting pneumonia; and turning into a chronic pain: the post-thoracotomy pain syndrome.

Traditional pain management in these groups of patients - such as opiate treatment, thoracic epidural analgesia, and non-opioid drugs - may have serious side effects. Large doses of opiates suppress the cough reflex and lead to respiratory depression with subsequent re-intubation and re-ventilation. Thoracic epidural analgesia, though being considered paramount among other analgesic options, requires a significant clinical experience. Still, it might be insufficient for satisfactory pain control and even complicated with pneumothorax, total spinal anaesthesia and inadvertent intravascular injection. Non-steroidal anti-inflammatory drugs (NSAIDs) and Tramadol are weak analgesics inadequate for severe pain control and might be responsible for gastrointestinal bleeding.

We suggest performing erector spinae plane block for intraoperative and postoperative pain management due to the ease of use and better analgesic effect. What remains is hard proof for the clinical efficacy and safety of this block, followed by a demonstration of the uptake of it in the hands of non-regional anaesthetists.


Eligibility criteria: Inclusion Criteria:

* all consecutive adult patients who undergo thoracic, spinal or abdominal surgery in Soroka Medical Center, and agree to participate in the study, older than 18 years, who meet criteria of ASA physical status I-II-III-IV class.

Exclusion Criteria:

* Unconscious or mentally incompetent patients or those who refuse to participate in the study.

Primary outcomes:
measure: Visual Analog Pain Score
timeFrame: 3 days
measure: Total pain med consumption in the PACU
timeFrame: 3 hours
measure: Length of stay in the PACU
timeFrame: 24 hours
Secondary outcomes:
measure: Length of hospital stay
timeFrame: 30 days
measure: Chronic pain development
timeFrame: 6 months
Other outcomes:
Locations:
city: Beersheba
country: Israel
facility: SorokaUMC
Study officials:
affiliation: Soroka University Medical Center
name: Michael Dubilet, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03898635: Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis
Official title: Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Tuberculous Meningitis
Keywords: linezolid
Lead sponsor: Huashan Hospital
Sponsor class: OTHER
First posted: 2019-04-02
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with central nervous system tuberculosis diagnosed and treated at Huashan Hospital.

Brief summary: Tuberculous meningitis (TBM) is the most serious form of Mycobacterium tuberculosis infection, causing mortality and disability in more than half of the patients. Current standard treatment for TBM is based on those developed to treat pulmonary tuberculosis, which does not take into account the differential ability of anti-tuberculosis drugs to penetrate the brain. With both good central nervous system penetrance and anti-tuberculosis efficacy that have been demonstrated in drug-resistant tuberculosis, linezolid may be a promising antimicrobial in TBM treatment. The purpose of this study is to evaluate the effectiveness of linezolid in the treatment of TBM.


Eligibility criteria: Inclusion Criteria:

* all patients diagnosed as TBM from the electronic medical record system.

Exclusion Criteria:

* Does not meet the established diagnostic criteria;
* Combine other pathogen central infections;
* Follow-up confirmed that the final diagnosis considers other diseases (such as tumors, autoimmune encephalitis, etc.);
* Our hospital has less than one week of anti-tuberculosis treatment;
* Lack of information

Primary outcomes:
measure: Survival
timeFrame: 5 years
Secondary outcomes:
measure: Number of participants with Medical Research Council grade deterioration
timeFrame: From the beginning of anti-tuberculosis treatment to the first documented progression, assessed up to 5 years.
Other outcomes:
measure: Time of Glasgow Coma Scale recovered to 15
timeFrame: From the beginning of anti-tuberculosis treatment to the first documented recovery, assessed up to 5 years.
measure: Time of body temperature returns to normal
timeFrame: From the beginning of anti-tuberculosis treatment to the first documented recovery, assessed up to 5 years.
measure: Number of participants with new omplications
timeFrame: From the beginning of anti-tuberculosis treatment to the first documented progression, assessed up to 5 years.
Locations:
city: Shanghai
country: China
facility: Infectious department of Huashan Hospital, Fudan University
Study officials:
References:
Clinical trial NCT01678235: Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus
Official title: The Impact Of Insulin Glulisine In Comparison With Aspart On Postprandial Glycemia After The High-Glycemic Index Meal In Children With Type 1 Diabetes - Cross-Over Double-Blind, Randomized Clinical Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Type 1 Diabetes Mellitus
Keywords: diabetes
insulin pump
glulisine
aspart
glycemic index
Lead sponsor: Medical University of Warsaw
Sponsor class: OTHER
First posted: 2012-09-03
Enrollment: 64
Sex: ALL
Minimum age (years): 10
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of this study is to determine whether insulin glulisine is more effective in postprandial glycemic control than insulin aspart after the H-GI meal in children with type 1 diabetes (T1DM) treated with insulin pump (CSII).

Detailed description: Some studies have suggested that insulin glulisine (GLU) has a slightly faster onset of action compared with insulin aspart (ASP). Meals of high glycemic index (H-GI) have distinct effect on postprandial glycaemia (PPG).

Eligibility criteria: Inclusion Criteria:

* Type 1 diabetes mellitus
* CSII for at least 3 months
* Duration of diabetes \> 1 years
* Informed consent

Exclusion Criteria:

* Concomitant dietary restrictions (e.g. celiac disease or food allergy)
* Diabetes related complications
* Baseline hyperglycemia \>150 mg/dl
* Any disease judged by the investigator to affect the trial

Primary outcomes:
measure: Postprandial glycemia
timeFrame: baseline, 30, 60, 90, 120 and 180 minutes after the breakfast
Secondary outcomes:
measure: Hypoglycemia episodes
timeFrame: 3-h study period
measure: Glucose Area Under the Curve (AUC)
timeFrame: 3-h study period
measure: Mean amplitude of glycemic excursion (MAGE)
timeFrame: 3-h study period
measure: Difference between the maximum and baseline glycemia
timeFrame: 3-h study period
Other outcomes:
measure: Questionnaire: Glycemic Index Knowledge
timeFrame: each subject was asked to fullfill the questionnaire before entering the study (day one)
Locations:
city: Warsaw
country: Poland
facility: Department of Pediatrics, Medical University of Warsaw, Poland
Study officials:
affiliation: Department of Pediatrics, Medical University of Warsaw, Poland
name: Katarzyna Dżygało, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Dzygalo K, Szypowska A. Impact of insulins glulisine and aspart on postprandial glycemia after a high-glycemic index meal in children with type 1 diabetes. Eur J Endocrinol. 2014 Mar 8;170(4):539-45. doi: 10.1530/EJE-13-0696. Print 2014 Apr.
Clinical trial NCT06654635: Ultrasound Guided Rhomboid Intercostal Plane Block Versus Thoracic Erector Spinae Plane Block in Upper Abdominal Surgery
Official title: Comparison Between Ultrasound Guided Rhomboid Intercostal Plane Block and Thoracic Erector Spinae Plane Block in Patients Undergoing Upper Abdominal Surgery: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Ultrasound
Rhomboid Intercostal Plane Block
Thoracic Erector Spinae Plane Block
Upper Abdominal Surgery
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2024-10-23
Enrollment: 60
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the work is to evaluate the analgesic efficacy of ultrasound guided rhomboid intercostal plane block versus ultrasound guided thoracic erector spinae block in patients undergoing upper abdominal surgery.

Detailed description: Abdominal surgery is one of the most definitive and mainstay treatment options for abdominal pathologies in clinical practice. Acute postoperative pain is a major challenge in the postoperative period.

The improved safety and efficacy that ultrasound brings to regional anesthesia helped promote its use and realize the benefits that regional anesthesia has over general anesthesia, such as decreased morbidity and mortality, superior postoperative analgesia, cost-effectiveness, decrease postoperative complications and an improved postoperative course .

Eligibility criteria: Inclusion Criteria:

* Patients aged 21-65 years.
* Both gender.
* American Society of Anesthesiologists (ASA) classification I-II.
* Presented for elective upper abdominal surgery.

Exclusion Criteria:

* Patients refused to participate.
* Patients with known or suspected allergy to the used medication.
* Patients with preoperative chronic pain.
* Patients with major cardiac, renal, respiratory, or hepatic disease.
* Patients with potential risk of coagulopathy.
* Obese patients with body mass index (BMI) \>35.

Primary outcomes:
measure: Total morphine consumption
timeFrame: 24 hours postoperatively
Secondary outcomes:
measure: Degree of pain
timeFrame: 24 hours postoperatively
measure: Time to 1st request of rescue analgesia
timeFrame: 24 hours postoperatively
measure: Heart rate
timeFrame: Every 15 min till the end of surgery
measure: Mean arterial blood pressure
timeFrame: Every 15 min till the end of surgery
measure: Incidence of side effects
timeFrame: 24 hours Postoperatively
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University
state: El-Gharbia
Study officials:
References:
Clinical trial NCT05435235: Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury
Official title: Dapagliflozin in the Prevention of Post-Coronary Intervention Acute Kidney Injury
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE4
Conditions: Acute Kidney Injury
Percutaneous Coronary Intervention
Keywords: SGLT2 inhibitor
Dapagliflozin
AKI
PCI
Angiography
Lead sponsor: Albert Einstein Healthcare Network
Sponsor class: OTHER
First posted: 2022-06-28
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To compare the incidence of acute kidney injury (AKI) post percutaneous coronary intervention (PCI) in a Dapagliflozin treated group versus a group managed with the usual standard of care.


Eligibility criteria: Inclusion Criteria:

1. Age 18 years or more.
2. Scheduled/non-emergent Percutaneous coronary intervention (PCI).
3. Post-index procedure Staged PCI with at least 14 days from contrast exposure.
4. Patient can fully understand the study information and sign informed consent.

Exclusion Criteria:

1. Cardiogenic shock /need for inotrope or mechanical pump support.
2. Acute kidney injury as defined by KDIGO criteria (\<4 weeks) prior to PCI.
3. End-Stage Renal Disease prior to PCI (On renal replacement therapy).
4. Diabetes Mellitus type 1.
5. Active diabetic ketoacidosis or uncontrolled hyperglycemia (blood glucose \>400 mg/dl).
6. ST-segment elevation Myocardial Infarction undergoing index PCI.
7. Active Genitourinary infection.
8. Diagnostic Left Heart Catheterization without PCI.
9. Patients undergoing zero contrast PCI.
10. Participation in a randomized controlled pharmaceutical or treatment-related cardiac or pulmonary clinical study within 1 month prior to randomization.
11. Coexistent hemodynamically significant valvulopathy (Symptomatic and/or severe).
12. Patients with Acute Heart Failure admission \< 30 days prior to PCI.
13. Intercurrent illness resulting in volume depletion and hypotension (MAP\<60 mmHg).
14. Patients with a kidney transplant.
15. Any contrast exposure within 14 days.
16. Patients with estimated glomerular filtration rate (eGFR) \< 25 cc/min (Recommended eGFR threshold by Food and Drug Administration labeling).
17. Patients with an active intrinsic inflammatory or autoimmune renal pathology.
18. Women of child bearing age (\<50 years old).
19. Prison Inmates

Primary outcomes:
measure: Acute Kidney Injury
timeFrame: Within 7 days.
Secondary outcomes:
measure: Length of hospital stay
timeFrame: 7 days
measure: Incidence of genitourinary infections
timeFrame: 7 days
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Einstein Medical Center
state: Pennsylvania
Study officials:
References: